Piracetam dosage and dilution
Piracetam is a nootropic/cognitive enhancer. Here's a quick overview before I check the medical library:
- Oral dose: typically 1.6-4.8 g/day in 2-3 divided doses
- IV/IM dose: 4-12 g/day in clinical settings (e.g., myoclonus, stroke)
- Dilution (IV): usually diluted in NS or D5W for infusion
- Renal adjustment: required - dose reduced proportionally to creatinine clearance
Searching sources...
Reading File
Searching the Web
Piracetam dosage dilution IV administration clinical
Now let me search the medical library for piracetam specifically, and also extract more detail from the official SPC:
Finding Sources
Reading Web Page
https://www.e-lactancia.org/media/papers/Piracetam-DS-UCB201…
Let me read the relevant textbook sections and get the full SPC dosing information:
Reading File
Reading Web Page
https://db.cbg-meb.nl/veegactie/csp/piracetam-6-2010.pdf
I now have comprehensive information from official sources. Here is the complete, well-organised answer:
Piracetam - Dosage & Dilution
Available Formulations
| Form | Strength |
|---|---|
| Film-coated tablets | 800 mg, 1200 mg |
| Oral solution | 20% (200 mg/ml), 33% (333 mg/ml) |
| Injection ampoules | 3 g / 15 ml |
Dosing by Indication
Cortical Myoclonus
- Start: 7.2 g/day
- Escalate: increase by 4.8 g every 3-4 days
- Maximum: 24 g/day in 2-3 divided doses
- Taper by 1.2 g every 2 days (or every 3-4 days for Lance-Adams syndrome) to avoid withdrawal seizures
- Textbooks cite 8-20 g/day as the typical maintenance range
Psycho-organic Syndromes / Vertigo
- 2.4-4.8 g/day in 2-3 divided doses
Dyslexia (Children ≥8 years)
- ~3.2 g/day in 2 divided doses
Sickle Cell Vaso-occlusive Crisis
- Prophylaxis: 160 mg/kg/day orally
- Remission: 300 mg/kg/day IV
- Doses below 160 mg/kg/day or irregular intake risk relapse
General Cognitive / Nootropic Use (adults, off-label)
- 1,200-4,800 mg/day; commonly 1,600 mg three times daily (4,800 mg/day total)
Children (breath-holding spells, off-label)
- 40-100 mg/kg/day (40-50 mg/kg most commonly used)
Parenteral Administration & Dilution
Injection (bolus/slow IV)
- Administer the 3 g/15 ml ampoule intravenously over several minutes (slow IV push)
- No further dilution required for bolus injection
Continuous IV Infusion
- Administer the total recommended daily dose continuously over 24 hours
- Compatible diluents (stability demonstrated up to 24 hours):
| Diluent | Concentrations |
|---|---|
| Glucose | 5%, 10%, 20% |
| Fructose | 5%, 10%, 20% |
| Sodium Chloride 0.9% (Normal Saline) | - |
| Dextran 40 (10% in 0.9% NaCl) | - |
| Ringer solution | - |
| Mannitol 20% | - |
| HES (Hydroxy Ethyl Starch) 6% and 10% | - |
No known incompatibilities with the above diluents.
Renal Dose Adjustment (MANDATORY)
Piracetam is entirely renally excreted (80-100% unchanged in urine) with a plasma half-life of ~5 hours in adults. Dose must be adjusted based on creatinine clearance (CrCl):
| Renal Function | CrCl (ml/min) | Dose Adjustment | Frequency |
|---|---|---|---|
| Normal | >80 | Full usual dose | 2-4 divided doses |
| Mild impairment | 50-79 | 2/3 usual dose | 2-3 divided doses |
| Moderate impairment | 30-49 | 1/3 usual dose | 2 divided doses |
| Severe impairment | <30 | 1/6 usual dose | Single daily dose |
| End-stage renal disease | - | Contraindicated | - |
CrCl formula: Cockcroft-Gault
CrCl = [140 - age(years)] × weight(kg) × (0.85 if female) / [72 × serum creatinine (mg/dl)]Hepatic Impairment
- No dose adjustment needed for isolated hepatic impairment
- If hepatic AND renal impairment coexist, apply renal adjustment
Special Populations
| Population | Consideration |
|---|---|
| Elderly | Half-life prolonged due to reduced renal function - monitor CrCl regularly for long-term use |
| Pregnancy | Avoid unless benefit clearly outweighs risk; crosses placental barrier |
| Pediatrics | No formal PK studies; use weight-based dosing (mg/kg) as above |
Key Pharmacokinetic Notes
- Half-life: ~5 hours (plasma), ~8.5 hours (CSF)
- Not metabolised in the human body
- Linear PK over 0.8-12 g dose range
- Penetrates CNS, crosses placenta, enters RBC membranes; does NOT accumulate in adipose tissue
- Storage: 15-25°C, dry place
Contraindications
- Hypersensitivity to piracetam or other pyrrolidone derivatives
- End-stage renal disease
- Cerebral haemorrhage
- Caution in: history of haemorrhagic CVA, bleeding disorders, patients on anticoagulants or antiplatelet drugs (including low-dose aspirin), major surgery (including dental)
Sources: Nootropil (UCB Pharma) SPC; Piracetam Core Safety Profile (CBG-MEB); Harrison's Principles of Internal Medicine - Myoclonus dosing 8-20 g/day; Bradley & Daroff's Neurology in Clinical Practice.
This is a shared conversation. Sign in to Orris to start your own chat.